Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Breast Cancer

32 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCBRE1366

09/03/2014

Predictors of Post-Mastectomy Local-Regional Recurrence and Distant Metastases

Basic Science

VICCBRE1445

04/21/2014

Optical Imaging of Breast Tumors

Basic Science

VICCBRE03103

01/22/2004

Breast Tissue/Body Fluids Repository (SPORE)

Basic Science

VCCBRE0057

10/27/2000

Nashville Breast Health Study

Diagnostic

ECOGBREE4112

11/04/2015

Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)

Diagnostic

VICCBRE0588

03/07/2006

MRI Evaluation Of Breast Tumor Growth And Treatment Response (SPORE)

Other

ECOGBREE2Z04-M

06/11/2008

Quality of LIfe in Younger Breast Cancer Survivors

Other

CTSUBREC70301-M

06/11/2007

Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes

Other

VICCBRE0704

02/21/2007

Developing In-Vivo Models of Human Breast Cancer

Supportive Care

VICCBRE1438

06/19/2014

A Randomized Trial Evaluating Bioimpedance Spectroscopy versus Tape Measurement in the Prevention of Lymphedema following Locoregional Treatment for Breast Cancer

Treatment

VICCBRE1552

02/02/2016

A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)

Treatment

VICCBRE1546

12/01/2015

The Impact of HER2 Heterogeneity on the Treatment of Early- Stage HER2-Positive Breast Cancer: A Phase II Study of T- DM1 in Combination with Pertuzumab in the Preoperative Setting

Treatment

VICCPHI1588

11/27/2015

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Treatment

VICCHEMP1558

10/09/2015

A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Treatment

VICCBRE1543

09/30/2015

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of MPDL3280A (Anti−PD-L1 Antibody) in Combination with Nab-Paclitaxel Compared with Placebo with Nab-Paclitaxel for Patients with Previously Untreated Metastatic Triple -Negative Breast Cancer

Treatment

VICCBRE1374

06/15/2015

Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination with Enzalutamide in Patients with Androgen Receptor Positive Triple Negative Metastatic Breast Cancer

Treatment

VICCBREP14115

05/21/2015

An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Treatment

VICCBRE1480

03/31/2015

A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer

Treatment

VICCBRE1246

03/13/2015

Enhancing Efficacy of Chemotherapy in Triple-Negative/Basal-Like Breast Cancers by Targeting Macrophages: A Phase Ib/II Study of PLX3397 and Eribulin in Patients with Metastatic Breast Cancer

Treatment

VICCBRE1453

11/18/2014

A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients with FGF Aberrant Metastatic Breast Cancer

Treatment

VICCBRE1430

08/12/2014

A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

Treatment

VICCBRE1393

06/23/2014

A Phase II Randomized, Double-Blind Placebo Controlled, Study of Letrozole with or without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women with Hormone Receptor-Positive HER2-Negative Breast Cancer

Treatment

VICCBRE1391

04/24/2014

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician's Choice in Previously-Treated, HER2-Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Treatment

VICCBRE1320

08/16/2013

A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative Locally Recurrent or Metastatic Breast Cancer or Non-Small Cell Lung Cancer

Treatment

VICCBRE1298

04/19/2013

A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft? Axxent? eBx System at the Time of Breast Conservation Surgery for Early Stage Breast Cancer

Treatment

VICCBREP12116

03/25/2013

An Open-Label, Phase IA/IB/IIA Study of GDC-810 Alone or in Combination With Palbociclib and an LHRH Agonist in Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Treatment

VICCPHI1248

10/12/2012

An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Treatment

CTSUBRENB-43-M

04/26/2012

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Treatment

CTSUNSABPBREB-47-M

04/26/2012

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 

Treatment

CTSUBRENCCTGMA32-M

04/23/2012

A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

Treatment

CTSUBRES1007-M

05/25/2011

Phase III randomized trial of standard adjuvant endocrine therapy +/- chemo in patients with 1-3 positive nodes, hormone receptor positive and Her2 negative breast cancer with recurrence score (RS) of 25 or less

Treatment

CTSUBREC40603-M

12/07/2010

Randomized Phase II 2 X 2 Factorial Trial Of The Addition Of Carboplatin +/- Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed By Dose-Dense AC In Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer